Cara Therapeutics, Inc. (CARA) News

Cara Therapeutics, Inc. (CARA): $9.27

0.39 (+4.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CARA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter CARA News Items

CARA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CARA News Highlights

  • CARA's 30 day story count now stands at 7.
  • Over the past 22 days, the trend for CARA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • CONN, DRUG and RYAN are the most mentioned tickers in articles about CARA.

Latest CARA News From Around the Web

Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients. “The NDA submission represents important progress toward brin

Yahoo | September 28, 2022

Needham Sticks to Its Buy Rating for Cara Therapeutics (CARA)

Needham analyst Joseph Stringer maintained a Buy rating on Cara Therapeutics (CARA - Research Report) today and set a price target of $26.00. The company's shares closed yesterday at $9.75.Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Cidara Therapeutics. According to TipRanks, Stringer has an average return of 3.5% and a 43.66% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cara Therapeutics with a $28.00 average price target.

Ryan Adist on TipRanks | September 21, 2022

Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | September 20, 2022

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company’s financial operations. “Ryan’s deep financial leadership experience will be instrument

Yahoo | September 12, 2022

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

Cara Therapeutics Inc (NASDAQ: CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP). Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life. The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress. The presentation includes data from 125 patients with NP and moderate-to-severe pruri

Yahoo | September 8, 2022

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch intensity was evident at Day 1 and effect was maintained through Week 8 – – Significantly greater proportion of patients who received oral difelikefalin vs. placebo achieved a complete response in WI-NRS at Week 8 – STAMFORD, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical compa

Yahoo | September 8, 2022

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET. A webcast of the presentation can be accessed under "Events & Pres

Yahoo | September 6, 2022

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NPSTAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual event focused on notalgia paresthetica (NP) on Tuesday, September 20, 2022, fr

Yahoo | August 24, 2022

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia parestheticaSTAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatm

Yahoo | August 22, 2022

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA® Regulatory decisions in Australia and Singapore expected by the end of 2022 ST. GALLEN, Switzerland, and STAMFORD, Conn., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA

Yahoo | August 19, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6159 seconds.